Get Integrated Data for Your Specialty and Interest Aresa
 
Category Select :
Items 1 ~ 20 of 1438, Page 1 of 73
1. Why We Screen for Some Cancers and Not Others - 09/09/2019
 American Cancer Society
  Screening tests are powerful tools in helping find cancer early or even preventing it. But they aren’t perfect. Find out what’s behind guidelines that tell us what screening tests to get and when.
2. Merck and Eisai Receive Third Breakthrough Therapy Designation from FDA for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment - 07/23/2019
 MERCK
  Designation Granted for Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment
3. WHO recommends dolutegravir as preferred HIV treatment option in all populations - 07/22/2019
 WHO
4. FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available - 07/17/2019
 MERCK
5. More Colorectal Cancer Diagnoses in People Under 55 Aren’t Only Because of More Colonoscopies - 07/12/2019
 American Cancer Society
  Colorectal cancer (CRC) is being diagnosed more often in the United States among adults younger than age 55. Does this mean more of them are getting colorectal cancer? Or are doctors finding it more often because more younger adults are having colonoscopies? In a study published in the Journal of Medical Screening, researchers at the American Cancer Society (ACS) ...
6. WHO updates global guidance on medicines and diagnostic tests to address health challenges, prioritize highly effective therapeutics, and improve affordable access - 07/09/2019
 WHO
  New essential medicines and diagnostics lists published today
7. More than a million people to be vaccinated in phase 2 of a huge cholera vaccination campaign in the Democratic Republic of the Congo - 07/03/2019
 WHO
8. CDC Advisory Committee on Immunization Practices (ACIP) Unanimously Votes to Provisionally Update Recommendations for Hepatitis A Vaccination - 06/27/2019
 MERCK
9. In the face of slow progress, WHO offers a new tool and sets a target to accelerate action against antimicrobial resistance - 06/18/2019
 WHO
10. New Research from Merck’s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting - 05/15/2019
 MERCK
  First-Time Data from POLO Trial Evaluating LYNPARZA ® (olaparib) in Germline BRCA-Mutated Metastatic Pancreatic Cancer in Plenary Session and ASCO Press Program / KEYTRUDA ® (pembrolizumab) Five-Year Survival Data in Advanced Non-Small Cell Lung Cancer (NSCLC) from KEYNOTE-001 Trial in ASCO Press Program / Overall Survival Data for KEYTRUDA in Metastatic Renal Cell Carcinoma (RCC), Recurrent/Metastatic Head and Neck Cancer and Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer
11. Death Rates from Liver Cancer Are Increasing, Especially in Men with Less Education - 04/26/2019
 American Cancer Society
  Education Trends in Liver Cancer Death Rates / HCV Infection Trends in Liver Cancer Death Rates
12. Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma - 04/25/2019
 MERCK
13. Statement from Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on continued efforts to assess duodenoscope contamination risk - 04/12/2019
 U.S. FOOD & DRUG ADMINISTRATION
14. Study Ties Whole Grains to Lower Risk of Liver Cancer - 02/27/2019
 American Cancer Society
  A large observational study shows eating more whole-grain foods may be linked to a lower risk of getting liver cancer.
15. Colorectal Cancer Screening: What Are My Options? - 02/26/2019
 American Cancer Society
  Are you wary of colonoscopies? Don’t let that keep you from getting checked for colorectal cancer. There are several options for tests, and one of them might be right for you.
16. FDA Accepts for Review New Drug Application (NDA) for Merck’s Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA® (Ceftolozane and Tazobactam) - 02/05/2019
 MERCK
17. FDA statement from Commissioner announcing efforts to improve the quality of the information used to assess the effectiveness of REMS programs in supporting the safe use of medications - 01/24/2019
 U.S. FOOD & DRUG ADMINISTRATION
  Risk Evaluation and Mitigation Strategy (REMS)
18. U.S. FDA Accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) - 01/22/2019
 MERCK
  Potential New Indication Would Expand Use to Allow Treatment-Experienced Adults Living with HIV-1 Whose Virus is Suppressed to Switch to PIFELTRO (in Combination with Other Antiretrovirals) or DELSTRIGO
19. Merck’s KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10) - 01/14/2019
 MERCK
  Results from Phase 3 KEYNOTE-181 Trial to be Presented at 2019 Gastrointestinal Cancers Symposium (ASCO GI)
20. 2018 in Review: New Cancer Drug Approvals - 12/28/2018
 American Cancer Society
  In 2018, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
<<  <  [1[2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  [10]  >  >>
 


Copyright ~2018 by Medisurf. All Rights Reserved Terms of Service Privacy Email : medalls@medalls.com